Company profile: Turning Point Therapeutics
1.1 - Company Overview
Company description
- Provider of structure-based drug discovery and development of precision medicines for cancer and other diseases, focusing on novel chemical identities for established oncogene drivers with secondary resistant mutations and newly identified disease-driven targets.
Products and services
- OPDIVO (nivolumab): Immunotherapy-class medication used for treating various types of cancer, applied across multiple cancer indications and oncology care contexts
- ELIQUIS (apixaban): Clinical-grade medication used to reduce the risk of stroke and blood clots in people with atrial fibrillation, supporting risk reduction in this cardiovascular condition
- REVLIMID (lenalidomide): Oncology-grade treatment for multiple myeloma and other blood cancers, applied to manage these blood cancer indications within oncology practice
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Turning Point Therapeutics
ArQule
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of cancer therapeutics, employing its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, including ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArQule company profile →
Aprea Therapeutics
HQ: Sweden
Website
- Description: Provider of oncology therapeutics focused on discovering and developing anticancer compounds that reactivate the tumor suppressor protein p53, including APR-246, a first-in-class small molecule drug candidate in clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aprea Therapeutics company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Mirna Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-directed oncology therapies as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Turning Point Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Turning Point Therapeutics
2.2 - Growth funds investing in similar companies to Turning Point Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Turning Point Therapeutics
4.2 - Public trading comparable groups for Turning Point Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →